In one large-scale study, mean life expectancy was 62 years among patients with hereditary PCC/PGL; however, SDHB mutations are associated with more aggressive disease in terms of early age at diagnosis, higher metastatic potential, recurrence, and the development of other primary malignancies (PCC, PGL, and renal cell carcinomas) [36, 37]. This evidence concerns the gene SDHB and renal cell carcinoma.